Cytokinetics, Incorporated Cytokinetics, Incorporated

Cytokinetics, Incorporated

CYTK

株式のランク #2308
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
株価
$62.08
最終同期: 2026-10-19
時価総額
$8.63B
変化(1日)
0.21%
変化(1年)
4.60%
国
US
取引 Cytokinetics, Incorporated (CYTK)

カテゴリー

Healthcare
Cytokinetics, Incorporated(CYTK)の配当利回りの履歴
Cytokinetics, Incorporated(銘柄コード: CYTK)の配当利回り(TTM)は2023-12-31時点で0.00%です。
過去5年間の平均配当利回り: 0.00%
Cytokinetics, Incorporated(CYTK)の2000から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
年 配当利回り 変化
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
2008 0.00% 0.00%
2007 0.00% 0.00%
2006 0.00% 0.00%
2005 0.00% 0.00%
2004 0.00% 0.00%
2003 0.00% 0.00%
2002 0.00% 0.00%
2001 0.00% 0.00%
2000 0.00% 0.00%
類似企業または競合他社の配当利回り(TTM)